Clinical Trial Detail

NCT ID NCT03041636
Title Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic lymphocytic leukemia

Therapies

Ruxolitinib

Age Groups: senior adult

No variant requirements are available.